EP0222834A1 - Traitement de la dyspepsie non ulcereuse avec des sels de bismuth - Google Patents

Traitement de la dyspepsie non ulcereuse avec des sels de bismuth

Info

Publication number
EP0222834A1
EP0222834A1 EP86903120A EP86903120A EP0222834A1 EP 0222834 A1 EP0222834 A1 EP 0222834A1 EP 86903120 A EP86903120 A EP 86903120A EP 86903120 A EP86903120 A EP 86903120A EP 0222834 A1 EP0222834 A1 EP 0222834A1
Authority
EP
European Patent Office
Prior art keywords
antibiotics
ulcer dyspepsia
bismuth salt
treatment
antibiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP86903120A
Other languages
German (de)
English (en)
Other versions
EP0222834A4 (fr
Inventor
T. J. Borody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3771057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0222834(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of EP0222834A1 publication Critical patent/EP0222834A1/fr
Publication of EP0222834A4 publication Critical patent/EP0222834A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/29—Antimony or bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • Non-ulcer dyspepsia has not been widely recognised in the past as being a single disease process and has been considered as comprising various disorders with such names as "nervous dyspepsia", “irritable bowel syndrome”, “gastritis”, and also "post-cholecystectomy syndrome".
  • Non-ulcer dyspepsia is characterised by epigastric discomfort, burning or pain, abdominal distention, bloating, belching or burping, nausea, and frequently it is said that the ingestion of food can precipitate such symptoms.
  • the present invention relates to a method of treating non-ulcer dyspepsia in patients suffering from the said non-ulcer dyspepsia, comprising administering to the said patients an effective amount of a pharmaceutically acceptable bismuth salt.
  • a preferred bismuth compound for the treatment of non- * ⁇ lcer dyspepsia is tripotassium dicitratobismuthate. This is also known as De-Nol (Registered Trade Mark). Other bismuth compounds known for the treatment of ulcer and other diseases may also be used in the present invention. Ideally, the bismuth salt is administered orally for a period of at least four (4) weeks and may be administered alone in an adequate dose or in combination with other antibiotics.
  • antibiotics may be chosen from the classes consisting of ⁇ -lactams, such as penicillins; macrolide antibiotics; tetracycline antibiotics and nitro-imidazole sulfones. From within these classes Amoxycillin, Erythromycin, Tetracycline and Tinidazole have been found to be particularly efficacious.
  • Another aspect of the invention comprises a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable bismuth salt, an antibiotic and pharmaceutieally acceptable carrier or diluent.
  • the bismuth salt is tripotassium dicitrato-bismuthate.
  • the most preferable antibiotics are selected from the classes specified above.
  • the ⁇ -lactam antibiotics Most preferably, the antibiotic is Amoxycillin.
  • the pharmaceutical composition is preferably presented in a form suitable for peroral administration, such as liquid, tablet or capsule form.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Traitement de la dyspepsie non ulcéreuse associée à une infection par le Campylobacter pyloridis par administration de sels de bismuth. L'administration de sels de bismuth en association avec des antibiotiques s'est révélée particulièrement efficace. Une composition pharmaceutique destinée à être utilisée avec la présente invention est également décrite.
EP19860903120 1985-04-18 1986-04-18 Traitement de la dyspepsie non ulcereuse avec des sels de bismuth. Ceased EP0222834A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPH019885 1985-04-18
AU198/85 1985-04-18

Publications (2)

Publication Number Publication Date
EP0222834A1 true EP0222834A1 (fr) 1987-05-27
EP0222834A4 EP0222834A4 (fr) 1989-10-04

Family

ID=3771057

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19860903120 Ceased EP0222834A4 (fr) 1985-04-18 1986-04-18 Traitement de la dyspepsie non ulcereuse avec des sels de bismuth.

Country Status (5)

Country Link
EP (1) EP0222834A4 (fr)
JP (1) JPS62502967A (fr)
AU (1) AU590578B2 (fr)
SG (1) SG72632A1 (fr)
WO (1) WO1986005981A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE135582T1 (de) * 1985-06-13 1996-04-15 Barry James Marshall Verfahren und zusammensetzungen zur behandlung von gastrointestinalen störungen
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
ATE81011T1 (de) * 1987-03-09 1992-10-15 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
JP2733849B2 (ja) * 1987-10-12 1998-03-30 ボロディー，ソーマス・ユリウス 胃腸障害治療のための改良された方法
AU623868B2 (en) * 1987-10-12 1992-05-28 Capability Services Pty. Limited Improved method for treatment of gastrointestinal disorders
US4935406A (en) * 1988-09-20 1990-06-19 Marion Laboratories, Inc. Use of bismuth (phosph/sulf)ated saccharides against Camplyobacter-associated gastrointestinal disorders
EP0375068A1 (fr) * 1988-12-23 1990-06-27 Gist-Brocades N.V. Associations de composés de bismuth et de tétracyclines
EP0403048A3 (fr) * 1989-06-14 1991-01-30 Warner-Lambert Company Un modèle de structure de système craniomandibulaire humain
FI910088A (fi) * 1990-01-09 1991-07-10 Gist Brocades Nv Oral farmaceutisk komposition.
YU45590A (sh) * 1990-03-07 1992-07-20 PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
US5192752A (en) * 1991-01-14 1993-03-09 The Procter & Gamble Company Swallowable pharmaceutical compositions containing colloidal bismuth subcitrate
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
DE59309771D1 (de) * 1993-05-11 1999-10-14 Spirig Ag Festes bismut- und amoxycillinhaltiges Arzneipräparat und seine Verwendung
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US6902738B2 (en) 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
PE48297A1 (es) * 1995-05-09 1998-02-04 Procter & Gamble Metodos y composiciones para la prevencion y el tratamiento de desordenes gastrointestinales
US5744168A (en) * 1995-12-07 1998-04-28 The Procter & Gamble Company Methods and compositions for the prevention and treatment of gastrointestinal disorders
US6051604A (en) * 1995-12-07 2000-04-18 The Proctor & Gamble Company Methods and compositions for the prevention and treatment of gastrointestinal disorders
US5702729A (en) * 1995-12-07 1997-12-30 The Procter & Gamble Company Methods for the prevention and treatment of gastrointestinal disorders caused or mediated by algae or cyanobacteria
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
MX355760B (es) 2010-12-13 2018-04-27 Salix Pharmaceuticals Inc Formulaciones gástricas y colónicas y métodos para elaborar y usar las mismas.
DK2877163T3 (en) 2012-07-27 2019-04-15 Redhill Biopharma Ltd FORMULATIONS AND PROCEDURES FOR THE PREPARATION OF FORMS FOR USING GAS DRAINAGE

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6063965A (en) * 1965-06-25 1967-01-05 Morton W. Scott Belayed acting compositions
US3621094A (en) * 1968-04-05 1971-11-16 Smith Kline French Lab Concentrated aqueous liquid antacid compositions containing certain phosphate and gluconate salts
GB1269987A (en) * 1968-04-18 1972-04-12 Garland Richard Brown Antacid composition
GB1220819A (en) * 1968-04-24 1971-01-27 Mar Pha Soc D Etude Et D Expl Improved bismuth salt
US4153685A (en) * 1968-11-23 1979-05-08 Schering Corporation Bismuth complex preparations
FR2029402A1 (fr) * 1969-01-28 1970-10-23 Breive Et Son Jib Labo Produit destiné à régulariser la digestion dans l'estomac et l'intestin
FR2053002A1 (en) * 1969-06-21 1971-04-16 Clin Midy Bismuth slats of alpha methiminobenzyl - penicillin
FR2073254A2 (en) * 1969-12-04 1971-10-01 Dausse Laboratoire Gum guar stabilised suspensions - of insoluble medicaments for treati gastrointestinal disorders
AU440535B2 (en) * 1969-12-18 1973-09-17 Export Drugs Company Antacid compositions
FR2092636A1 (en) * 1970-06-03 1972-01-28 Griffon Henri Dried yeast - bismuth subnitrate compositions - for gastrointestinal disorders
ZA74385B (en) * 1974-01-18 1975-08-27 Gist Brocades Nv Pharmaceutical compositions
HU179474B (en) * 1978-02-24 1982-10-28 Laszlo Gyarmati Process for preparing solid oral pharmaceutical compositons with increased length of activity and with a regulated release of the active material
PH20649A (en) * 1981-09-22 1987-03-16 Gist Brocades Nv Bismuth containing composition and method for the preparation thereof
US4588589A (en) * 1983-10-13 1986-05-13 Richardson-Vicks Inc. Antidiarrheal compositions and use thereof
ATE135582T1 (de) * 1985-06-13 1996-04-15 Barry James Marshall Verfahren und zusammensetzungen zur behandlung von gastrointestinalen störungen
EP0206627B1 (fr) * 1985-06-13 1992-08-12 Barry James Dr. Marshall Méthodes de traitement d'affections gastro-intestinales

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 23, no. 5, May 1983, pages 796-797, American Society for Micrbiology; J. MICHEL et al.: "Susceptibility of clinical isolates of campylobacter jejuni to sixteen antimicrobial agents" *
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 28, no. 6, December 1985, pages 837-838, American Society for Microbiology; C.A.M. McNULTY et al.: "Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents" *
CAMPYLOBACTER III, PROCEEDINGS OF THE THIRD INTERNATIONAL WORKSHOP ON CAMPYLOBACTER INFECTION, Ottawa, 7th-10th July 1985, page 161, abstract no. 097, Public Health Laboratory Service, London, GB; D.M. JONES et al.: "The effects of various anti-ulcer regimens and antibiotics on the presence of Campylobacter pyloridis and its antibody" *
CAMPYLOBACTER III, PROCEEDINGS OF THE THIRD INTERNATIONAL WORKSHOP ON CAMPYLOBACTER INFECTION, Ottawa, 7th-10th July 1985, page 162, abstract no. 098, Public Health Laboratory Service, London, GB; M.L. LANGENBERG et al.: "The pathogenic role of campylobacter pyloridis studied by attempts to eliminate these organisms" *
CAMPYLOBACTER III, PROCEEDINGS OF THE THIRD INTERNATIONAL WORKSHOP ON CAMPYLOBACTER INFECTION, Ottawa, 7th-10th July 1985, page 163, abstract no. 099, Public Health Laboratory Service, London, GB; C.A.M. McNULTY et al.: "A trial to compare treatment with pepto-bismol (bismuth subsalicylate), placebo and erythromycin for the eradication of campylobacter pyloridis in patients with gastritis" *
CAMPYLOBACTER III, PROCEEDINGS OF THE THIRD INTERNATIONAL WORKSHOP ON CAMPYLOBACTER INFECTION, Ottawa, 7th-10th July 1985, pages 165,166, abstract no. 100, Public Health Laboratory Service, London, GB; B.J. MARSHALL et al.: "The antibacterial action of bismuth: early results of antibacterial regimens in the treatment of duodenal ulcer" *
GASTROENTEROLOGY, vol. 88, no. 5, 1985, page 1462; J.R. LAMBERT et al.: "Campylobacter like organisms (CLO) - in vivo and in vitro susceptibility to antimicrobial and antiulcer therapy" *
IMMUNIT[T UND INFEKTION, vol. 14, no. 2, April 1986, pages 58-62; G. KASPER et al.: "Klinische Bedeutung, Epidemiologie und Laboratoriumsdiagnostik von Campylobacter pyloridis" *
J. CLIN. PATHOL., vol. 39, 1986, pages 353-365; C.S. GOODWIN et al.: "Campylobacter pyloridis, gastritis, and peptic ulceration" *
See also references of WO8605981A1 *
THE JOURNAL OF INFECTIOUS DISEASES, vol. 153, no. 4, April 1986, pages 650-657; B.J. MARSHALL: "Campylobacter pyloridis and gastritis" *
THE LANCET, 15th August 1987, page 398; B.J. RATHBONE et al.: "Campylobacter pylori and peptic ulcer" *
THE MEDICAL JOURNAL OF AUSTRALIA, vol. 142, 15th April 1985, pages 439-444; B.J. MARSHALL et al.: "Pyloric campylobacter infection and gastroduodenal disease" *

Also Published As

Publication number Publication date
EP0222834A4 (fr) 1989-10-04
AU590578B2 (en) 1989-11-09
SG72632A1 (en) 2000-05-23
JPS62502967A (ja) 1987-11-26
WO1986005981A1 (fr) 1986-10-23
AU5902686A (en) 1986-11-05

Similar Documents

Publication Publication Date Title
AU590578B2 (en) Treatment of non-ulcer dyspepsia with bismuth salts
US5256684A (en) Methods and compositions for the treatment of gastrointestinal disorders
US5601848A (en) Methods for the treatment of gastrointestinal disorders
CA1277232C (fr) Methodes et composes pour le traitement des troubles gastro-intestinaux
US5629297A (en) Medicament for treating gastrointestinal disorders
Hewitt The penicillins: a review of strategy and tactics
EP0219912B1 (fr) L'utilisation du nitrofurantoine pour le traitement et la prophylaxie des maladies gastro-intestinales
Breese et al. Prevention of rheumatic fever
EP0591446B1 (fr) Procede de traitement des gastrites a helicobacter pylori
Ndinya-Achola et al. Three day oral course of Augmentin to treat chancroid.
CN1204881C (zh) 烯丙胺衍生物在制备治疗幽门螺杆菌感染和相关疾病的药物方面的用途
Glupczynski In vitro susceptibility of Helicobacter pylori to antibiotics and bismuth salts and the importance of acquired resistance to antibiotics in treatment failures of H. pylori infection
US4997830A (en) Pharmaceutical composition for the treatment of periodontitis
Lim et al. Three regimens of procaine penicillin G, Augmentin, and probenecid compared for treating acute gonorrhoea in men.
Andersen et al. Pivmecillinam in the treatment of therapy resistant urinary tract infections: A comparison with pivmecillinam, pivampicillin and their combination
SU1748827A1 (ru) Способ лечени хронической стафилококковой инфекции
Byakod et al. Clinical evaluation of lincomycin, a new antibiotic
RU2187318C2 (ru) Способ лечения хронического гастрита и язвенной болезни двенадцатиперстной кишки
RU2076708C1 (ru) Фармацевтическая композиция и способ лечения и профилактики гастроэнтерологических заболеваний
Willcox Effective treatment of gonorrhoea in London with two oral doses of amoxycillin.
O’Morain How to eradicate Helicobacter pylori and prevent reinfection
Nsanze et al. Three day oral course of Augmentin to treat chancroid.
JPH08337529A (ja) 上部消化管疾患治療剤
UA35450A (uk) Спосіб запобігання рецидивів виразкової хвороби

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19870422

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE PROCTER & GAMBLE COMPANY

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BORODY, T. J.

A4 Supplementary search report drawn up and despatched

Effective date: 19891004

17Q First examination report despatched

Effective date: 19910723

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APAD Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOS REFNE

APBX Invitation to file observations in appeal sent

Free format text: ORIGINAL CODE: EPIDOSNOBA2E

APBX Invitation to file observations in appeal sent

Free format text: ORIGINAL CODE: EPIDOSNOBA2E

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19981110

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE